Novel immunotherapeutic strategies of gastric cancer treatment

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Amedei, Amedeo ^a,b   Benagiano, Marisa ^a   Della Bella, Chiara ^a   Niccolai, Elena ^a   D'Elios, Mario M ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda Ospedaliera Universitaria   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLT3 LIGAND; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 21; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; MYC PROTEIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RITUXIMAB; SMALL INTERFERING RNA; TRASTUZUMAB; VASCULOTROPIN A;

ADOPTIVE TRANSFER; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON PERFORATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIARRHEA; DNA MODIFICATION; ESOPHAGITIS; ESOPHAGUS TUMOR; GASTROINTESTINAL CARCINOMA; HUMAN; HYPERTENSION; INNATE IMMUNITY; LOWER ESOPHAGUS SPHINCTER; MOLECULAR BIOLOGY; NATURAL KILLER CELL; NEUTROPENIA; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; T LYMPHOCYTE; UPREGULATION; ADENOCARCINOMA; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; STOMACH TUMOR;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855521731     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/437348     Document Type: Review

References (172)

1. Parkin D. M., International variation Oncogene 2004 23 38 6329 6340 (Pubitemid 39272833)
2. Bruckner H. W., Kufe D. W., Pollock R. E., Weichselbaum R. R., Cancer Medicine 2003 Ontario, Canda
3. Cunningham D., Allum W. H., Stenning S. P., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer New England Journal of Medicine 2006 355 11 20
4. Tepper J., Krasna M. J., Niedzwiecki D., Hollis D., Reed C. E., Goldberg R., Kiel K., Willett C., Sugarbaker D., Mayer R., Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 Journal of Clinical Oncology 2008 26 7 1086 1092
5. Walsh T. N., Noonan N., Hollywood D., Kelly A., Keeling N., Hennessy T. P., A comparison of multimodal therapy and surgery for esophageal adenocarcinoma New England Journal of Medicine 1996 335 7 462 467 (Pubitemid 26269945)
6. Macdonald J. S., Smalley S. R., Benedetti J., Hundahl S. A., Estes N. C., Stemmermann G. N., Haller D. G., Ajani J. A., Gunderson L. L., Milburn Jessup J., Martenson J. A., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction New England Journal of Medicine 2001 345 10 725 730
7. Kelsen D. P., Ginsberg R., Pajak T. F., Sheahan D. G., Gunderson L., Mortimer J., Estes N., Haller D. G., Ajani J., Kocha W., Minsky B. D., Roth J. A., Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer New England Journal of Medicine 1998 339 27 1979 1984 (Pubitemid 29024130)
8. Enzinger P. C., Mayer R. J., Esophageal cancer New England Journal of Medicine 2003 349 23 2241 2252 (Pubitemid 37485141)
9. Vanhoefer U., Tewes M., Rojo F., Dirsch O., Schleucher N., Rosen O., Tillner J., Kovar A., Braun A. H., Trarbach T., Seeber S., Harstrick A., Baselga J., Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor Journal of Clinical Oncology 2004 22 1 175 184 (Pubitemid 41095130)
10. Shah M. A., Ramanathan R. K., Ilson D. H., Levnor A., D'Adamo D., O'Reilly E., Tse A., Trocola R., Schwartz L., Capanu M., Schwartz G. K., Kelsen D. P., Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma Journal of Clinical Oncology 2006 24 33 5201 5206 (Pubitemid 46631363)
11. Ocean A. J., Schnoll-Sussman F., Keresztes R., Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA) Journal of Clinical Oncology 2006 18 14040
12. Elkord E., Hawkins R. E., Stern P. L., Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy Expert Opinion on Biological Therapy 2008 8 4 385 395 (Pubitemid 351570405)
13. Amedei A., Niccolai E., Della Bella C., Cianchi F., Trallori G., Benagiano M., Bencini L., Bernini M., Farsi M., Moretti R., Del Prete G., D'Elios M. M., Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma Cancer Immunology, Immunotherapy 2009 58 11 1819 1830
14. Goedert J. J., The epidemiology of acquired immunodeficiency syndrome malignancies Seminars in Oncology 2000 27 4 390 401 (Pubitemid 30626437)
15. Zeier M., Hartschuh W., Wiesel M., Lehnert T., Ritz E., Malignancy after renal transplantation American Journal of Kidney Diseases 2002 39 1 E5
16. Challis G. B., Stam H. J., The spontaneous regression of cancer. A review of cases from 1900 to 1987 Acta Oncologica 1990 29 5 545 550 (Pubitemid 20294725)
17. Zhang L., Conejo-Garcia J. R., Katsaros D., Gimotty P. A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M. N., Rubin S. C., Coukos G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer New England Journal of Medicine 2003 348 3 203 213 (Pubitemid 36077915)
18. Nagorsen D., Scheibenbogen C., Marincola F. M., Letsch A., Keilholz U., Natural T cell immunity against cancer Clinical Cancer Research 2003 9 12 4296 4303 (Pubitemid 37248383)
19. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors Nature Medicine 2003 9 6 669 676 (Pubitemid 36749215)
20. Zou W., Regulatory T cells, tumour immunity and immunotherapy Nature Reviews Immunology 2006 6 4 295 307
21. Celluzzi C. M., Mayordomo J. I., Storkus W. J., Lotze M. T., Falo L. D. Jr., Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity Journal of Experimental Medicine 1996 183 1 283 287 (Pubitemid 26028768)
22. Caux C., Ait-Yahia S., Chemin K., De Bouteiller O., Dieu-Nosjean M. C., Homey B., Massacrier C., Vanbervliet B., Zlotnik A., Vicari A., Dendritic cell biology and regulation of dendritic cell trafficking by chemokines Springer Seminars in Immunopathology 2000 22 4 345 369
23. Figdor C. G., Jolanda I., de Vries M., Joost Lesterhuis W., Melief C. J. M., Dendritic cell immunotherapy: mapping the way Nature Medicine 2004 10 5 475 480 (Pubitemid 38667904)
24. Gilboa E., DC-based cancer vaccines Journal of Clinical Investigation 2007 117 5 1195 1203 (Pubitemid 46718404)
25. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Xiangming C., Iwashige H., Aridome K., Hokita S., Aikou T., Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer Cancer Letters 2000 159 1 103 108
26. Ishigami S., Natsugoe S., Uenosono Y., Hata Y., Nakajo A., Miyazono F., Matsumoto M., Hokita S., Aikou T., Infiltration of antitumor immunocytes into the sentinel node in gastric cancer Journal of Gastrointestinal Surgery 2003 7 6 735 739 (Pubitemid 37103126)
27. Galetto A., Contarini M., Sapino A., Cassoni P., Consalvo E., Forno S., Pezzi C., Barnaba V., Mussa A., Matera L., Ex vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells Journal of Surgical Research 2001 100 1 32 38 (Pubitemid 32802700)
28. Kono K., Takahashi A., Sugai H., Fujii H., Choudhury A. R., Kiessling R., Matsumoto Y., Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer Clinical Cancer Research 2002 8 11 3394 3400 (Pubitemid 35340713)
29. Kim T. W., Hung C. F., Ling M., Juang J., He L., Hardwick J. M., Kumar S., Wu T. C., Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins Journal of Clinical Investigation 2003 112 1 109 117 (Pubitemid 38056382)
30. Zong W. X., Lindsten T., Ross A. J., MacGregor G. R., Thompson C. B., BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak Genes and Development 2001 15 12 1481 1486 (Pubitemid 32552527)
31. Kang T. H., Lee J. H., Noh K. H., Han H. D., Shin B. C., Choi E. Y., Peng S., Hung C. F., Wu T. C., Kim T. W., Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments International Journal of Cancer 2007 120 8 1696 1703 (Pubitemid 46399356)
32. Kim T. W., Hung C. F., Boyd D., Juang J., He L., Kim J. W., Hardwick J. M., Wu T. C., Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies Journal of Immunology 2003 171 6 2970 2976 (Pubitemid 37093519)
33. Kang T. H., Lee J. H., Noh K. H., Boyd D. A. K., Hardwick J. M., Hung C. F., Wu T. C., Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency Cancer Research 2005 65 1 309 316 (Pubitemid 40070823)
34. Park D., Lapteva N., Seethammagari M., Slawin K. M., Spencer D. M., An essential role for Akt1 in dendritic cell function and tumor immunotherapy Nature Biotechnology 2006 24 12 1581 1590 (Pubitemid 44967484)
35. Yu Q., Kovacs C., Yue F. Y., Ostrowski M. A., The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8 + T cell memory responses Journal of Immunology 2004 172 10 6047 6056 (Pubitemid 38621206)
36. Kim J. H., Kang T. H., Noh K. H., Kim S. H., Lee Y. H., Kim K. W., Bae H. C., Ahn Y. H., Choi E. Y., Kim J. S., Lee K. M., Kim T. W., Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN Immunology Letters 2010 134 1 47 54
37. Leslie N. R., Batty I. H., Maccario H., Davidson L., Downes C. P., Understanding PTEN regulation: PIP2, polarity and protein stability Oncogene 2008 27 41 5464 5476
38. Kim J. H., Kang T. H., Noh K. H., Bae H. C., Ahn Y. -H., Lee Y. -H., Choi E. Y., Chun K. -H., Lee S. -J., Kim T. W., Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency Clinical and Experimental Immunology 2011 165 2 180 189
39. He S. B., Sun K., Wang L., Li D. C., Zhang Y. Y., GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro Zhonghua Zhong Liu Za Zhi 2010 32 6 410 414
40. Kim S., Iizuka K., Aguila H. L., Weissman I. L., Yokoyama W. M., In vivo natural killer cell activities revealed by natural killer cell-deficient mice Proceedings of the National Academy of Sciences of the United States of America 2000 97 6 2731 2736 (Pubitemid 30159240)
41. Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M. A., Vallejo C., Martos J. A., Moreno M., The prognostic significance of intratumoral natural killer cells in patients with colerectal carcinoma Cancer 1997 79 12 2320 2328 (Pubitemid 27251014)
42. Orange J. S., Ballas Z. K., Natural killer cells in human health and disease Clinical Immunology 2006 118 1 1 10 (Pubitemid 43012040)
43. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A., Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes Journal of Experimental Medicine 1982 155 6 1823 1841 (Pubitemid 12074218)
44. Law T. M., Motzer R. J., Mazumdar M., Sell K. W., Walther P. J., O'Connell M., Khan A., Vlamis V., Vogelzang N. J., Bajorin D. F., Phase III randomized trial of interleukin-2 with or without lymphokine- activated killer cells in the treatment of patients with advanced renal cell carcinoma Cancer 1995 76 5 824 832
45. Kammula U. S., White D. E., Rosenberg S. A., Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer Cancer 1998 83 4 797 805 (Pubitemid 28387707)
46. Brune M., Castaigne S., Catalano J., Gehlsen K., Ho A. D., Hofmann W. K., Hogge D. E., Nilsson B., Or R., Romero A. I., Rowe J. M., Simonsson B., Spearing R., Stadtmauer E. A., Szer J., Wallhult E., Hellstrand K., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood 2006 108 1 88 96 (Pubitemid 43996626)
47. Atkins M. B., Lotze M. T., Dutcher J. P., Fisher R. I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S. A., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 Journal of Clinical Oncology 1999 17 7 2105 2116 (Pubitemid 29318842)
48. Bukowski R. M., Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2 Cancer 1997 80 7 1198 1220 (Pubitemid 27407220)
49. Gollob J. A., Mier J. W., Veenstra K., McDermott D. F., Clancy D., Clancy M., Atkins M. B., Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN- induction is associated with clinical response Clinical Cancer Research 2000 6 5 1678 1692 (Pubitemid 30305060)
50. Gollob J. A., Veenstra K. G., Parker R. A., Mier J. W., McDermott D. F., Clancy D., Tutin L., Koon H., Atkins M. B., Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma Journal of Clinical Oncology 2003 21 13 2564 2573 (Pubitemid 46606339)
51. Robertson M. J., Mier J. W., Logan T., Atkins M., Koon H., Koch K. M., Kathman S., Pandite L. N., Oei C., Kirby L. C., Jewell R. C., Bell W. N., Thurmond L. M., Weisenbach J., Roberts S., Dar M. M., Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer Clinical Cancer Research 2006 12 14 4265 4273
52. Davis I. D., Skrumsager B. K., Cebon J., Nicholaou T., Barlow J. W., Moller N. P. H., Skak K., Lundsgaard D., Frederiksen K. S., Thygesen P., McArthur G. A., An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma Clinical Cancer Research 2007 13 12 3630 3636 (Pubitemid 46955126)
53. de Castro F. A., Bonini Palma P. V., Morais F. R., Simes B. P., Carvalho P. V. B., Ismael S. J., Lima C. P., Voltarelli J. C., Immunological effects of interferon- on chronic myelogenous leukemia Leukemia and Lymphoma 2003 44 12 2061 2067 (Pubitemid 37369645)
54. Chen W., Chan A. S.H., Dawson A. J., Liang X., Blazar B. R., Miller J. S., FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function Biology of Blood and Marrow Transplantation 2005 11 1 23 34 (Pubitemid 40057990)
55. Gluck W. L., Hurst D., Yuen A., Levine A. M., Dayton M. A., Gockerman J. P., Lucas J., Denis-Mize K., Tong B., Navis D., Difrancesco A., Milan S., Wilson S. E., Wolin M., Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response Clinical Cancer Research 2004 10 7 2253 2264 (Pubitemid 38445682)
56. Khan K. D., Emmanouilides C., Benson D. M., Hurst D., Garcia P., Michelson G., Milan S., Ferketich A. K., Piro L., Leonard J. P., Porcu P., Eisenbeis C. F., Banks A. L., Chen L., Byrd J. C., Caligiuri M. A., A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma Clinical Cancer Research 2006 12 23 7046 7053 (Pubitemid 44974502)
57. Berdeja J. G., Hess A., Lucas D. M., O'Donnell P., Ambinder R. F., Diehl L. F., Carter-Brookins D., Newton S., Flinn I. W., Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab Clinical Cancer Research 2007 13 8 2392 2399 (Pubitemid 46698589)
58. Parihar R., Nadella P., Lewis A., Jensen R., De Hoff C., Dierksheide J. E., VanBuskirk A. M., Magro C. M., Young D. C., Shapiro C. L., Carson W. E., A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon production in a subset of patients Clinical Cancer Research 2004 10 15 5027 5037 (Pubitemid 39099777)
59. Renner C., Hartmann F., Jung W., Deisting C., Juwana M., Pfreundschuh M., Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody Cancer Immunology Immunotherapy 2000 49 3 173 180 (Pubitemid 30430067)
60. Hartmann F., Renner C., Jung W., Da Costa L., Tembrink S., Held G., Sek A., Knig J., Bauer S., Kloft M., Pfreundschuh M., Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines Clinical Cancer Research 2001 7 7 1873 1881 (Pubitemid 32994820)
61. Voskens C. J., Watanabe R., Rollins S., Campana D., Hasumi K., Mann D. L., Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity Journal of Experimental and Clinical Cancer Research 2010 29 1, article 134
62. Kitagawa Y., Ueda M., Ando N., Ozawa S., Shimizu N., Kitajima M., Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma Clinical Cancer Research 1996 2 5 909 914 (Pubitemid 26168944)
63. Gibault L., Metges J. P., Conan-Charlet V., Lozac'h P., Robaszkiewicz M., Bessaguet C., Lagarde N., Volant A., Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer British Journal of Cancer 2005 93 1 107 115 (Pubitemid 41076258)
64. Wilkinson N. W., Black J. D., Roukhadze E., Driscoll D., Smiley S., Hoshi H., Geradts J., Javle M., Brattain M., Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma Journal of Gastrointestinal Surgery 2004 8 4 448 453 (Pubitemid 38561209)
65. Allegra C. J., Jessup J. M., Somerfield M. R., Hamilton S. R., Hammond E. H., Hayes D. F., McAllister P. K., Morton R. F., Schilsky R. L., American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy Journal of Clinical Oncology 2009 27 12 2091 2096
66. Amado R. G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D. J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S. D., Chang D. D., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer Journal of Clinical Oncology 2008 26 10 1626 1634
67. van Cutsem E., Khne C. H., Hitre E., Zaluski J., Chien C. R. C., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J. K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer New England Journal of Medicine 2009 360 14 1408 1417
68. Baselga J., Norton L., Masui H., Pandiella A., Coplan K., Miller W. H., Mendelsohn J., Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies Journal of the National Cancer Institute 1993 85 16 1327 1333 (Pubitemid 23249725)
69. Kawaguchi Y., Kono K., Mimura K., Sugai H., Akaike H., Fujii H., Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma International Journal of Cancer 2007 120 4 781 787 (Pubitemid 46175397)
70. Imai K., Takaoka A., Comparing antibody and small-molecule therapies for cancer Nature Reviews Cancer 2006 6 9 714 727 (Pubitemid 44286003)
71. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer New England Journal of Medicine 2004 351 4 337 345 (Pubitemid 38944402)
72. Bonner J. A., Harari P. M., Giralt J., Azarnia N., Shin D. M., Cohen R. B., Jones C. U., Sur R., Raben D., Jassem J., Ove R., Kies M. S., Baselga J., Youssoufian H., Amellal N., Rowinsky E. K., Ang K. K., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck New England Journal of Medicine 2006 354 6 567 578 (Pubitemid 43209104)
73. Enzinger P., Yock T., Suh W., Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer Journal of Clinical Oncology 2006 24 4064
74. Safran H., Suntharalingam M., Dipetrillo T., Ng T., Doyle L. A., Krasna M., Plette A., Evans D., Wanebo H., Akerman P., Spector J., Kennedy N., Kennedy T., Cetuximab With concurrent chemoradiation for esophagogastric cancer: assessment of toxicity International Journal of Radiation Oncology Biology Physics 2008 70 2 391 395
75. Ruhstaller T., Pless M., Dietrich D., Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase lb-II trial (SAKK 75/06) Journal of Clinical Oncology 2011 29 626 631
76. de Vita F., Orditura M., Martinelli E., Vecchione L., Innocenti R., Sileni V. C., Pinto C., Di Maio M., Farella A., Troiani T., Morgillo F., Napolitano V., Ancona E., Di Martino N., Ruol A., Galizia G., Del Genio A., Ciardiello F., A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer British Journal of Cancer 2011 104 3 427 432
77. Agarwala A., Hanna N., McCollum A., Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: a pilot study from the Hoosier Oncology Group and the University of Texas Southwestern Journal of Clinical Oncology 2009 27 4557
78. Ma H., Ryan T., Newman E., Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation 58 Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO '09) 2009
79. Ilson D. H., Bains M., Kelsen D. P., O'Reilly E., Karpeh M., Coit D., Rusch V., Gonen M., Wilson K., Minsky B. D., Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer Journal of Clinical Oncology 2003 21 15 2926 2932 (Pubitemid 46621843)
80. Ku G., Bains M., Rizk N., Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: PET scan after induction therapy may identify early treatment failure 9 Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO '07) 2007
81. Moehler M., Mueller A., Trarbach T., Lordick F., Seufferlein T., Kubicka S., Geiler M., Schwarz S., Galle P. R., Kanzler S., Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study Annals of Oncology 2011 22 6 1358 1366
82. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pags C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Pags F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 5795 1960 1964 (Pubitemid 44498003)
83. Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 2002 298 5594 850 854 (Pubitemid 35231542)
84. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H., Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772 (Pubitemid 32691889)
85. June C. H., Principles of adoptive T cell cancer therapy Journal of Clinical Investigation 2007 117 5 1204 1212 (Pubitemid 46718405)
86. Gutenberg-Universitat Mainz J., Eberts D., Fatho M., Lennerz V., Melanoma-associated Mhc Class I associated oligopeptides and the uses thereof. WO/2007/025760, 2007
87. Pharmaceuticals A., Cytotoxic T Lymphocyte-stimulation peptides for prevention, treatment, and diagnosis of melanoma. WO/2001/032193, 2001
88. Yee C., Thompson J. A., Byrd D., Riddell S. R., Roche P., Celis E., Greenberg P. D., Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proceedings of the National Academy of Sciences of the United States of America 2002 99 25 16168 16173 (Pubitemid 35462767)
89. Kim Y. J., Lim J., Kang J. S., Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells Cancer Letters 2010 33 11 1789 1795
90. Sangiolo D., Cytokine induced killer cells as promising immunotherapy for solid tumors Journal of Cancer 2011 2 363 368
91. Hoshino T., Seki N., Kikuchi M., Kuramoto T., Iwamoto O., Kodama I., Koufuji K., Takeda J., Itoh K., Hla class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer International Journal of Cancer 1997 70 6 631 638 (Pubitemid 27158439)
92. Kono K., Rongcun Y., Charo J., Ichihara F., Celis E., Sette A., Appella E., Sekikawa T., Matsumoto Y., Kiessung R., Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes International Journal of Cancer 1998 78 2 202 208 (Pubitemid 28443178)
93. Guo D. L., Dong M., Wang L., Sun L. P., Yuan Y., Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases World Journal of Gastroenterology 2002 8 6 1009 1013 (Pubitemid 35446411)
94. Wu K., Nie Y., Guo C., Chen Y., Ding J., Fan D., Molecular basis of therapeutic approaches to gastric cancer Journal of Gastroenterology and Hepatology 2009 24 1 37 41
95. Nie Y., Wu K., Yang J., Tian F., Li L., Chen B., Fan D., Induction of T lymphocytes specific to human gastric cancer using HLA-A matched allogeneic gastric tumor cells Journal of Immunotherapy 2003 26 5 403 411 (Pubitemid 37128552)
96. Jiang J., Xu N., Wu C., Deng H., Lu M., Li M., Xu B., Wu J., Wang R., Xu J., Nilsson-Ehle P., Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells Anticancer Research 2006 26 3 B 2237 2242 (Pubitemid 43980179)
97. Wu C., Jiang J., Shi L., Xu N., Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer Anticancer Research 2008 28 6 B 3997 4002
98. Sun S., Li X. M., Li X. D., Yang W. S., Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines Cancer Biotherapy and Radiopharmaceuticals 2005 20 2 173 180 (Pubitemid 40696099)
99. Alexander R. B., Rosenberg S. A., Long term survival of adoptively transferred tumor-infiltrating lymphocytes in mice Journal of Immunology 1990 145 5 1615 1620 (Pubitemid 20255077)
100. Kono K., Takahashi A., Ichihara F., Amemiya H., Iizuka H., Fujii H., Sekikawa T., Matsumoto Y., Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial Clinical Cancer Research 2002 8 6 1767 1771 (Pubitemid 34633733)
101. Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2 Journal of the National Cancer Institute 1994 86 15 1159 1166 (Pubitemid 24249302)
102. Dudley M. E., Wunderlich J. R., Shelton T. E., Even J., Rosenberg S. A., Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients Journal of Immunotherapy 2003 26 4 332 342 (Pubitemid 36858717)
103. Tomov M., Melichar B., Sedlkov I., teiner I., Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma Gynecologic Oncology 2008 108 2 415 420 (Pubitemid 351174290)
104. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pags C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Pags F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 5795 1960 1964 (Pubitemid 44498003)
105. Ho W. Y., Blattman J. N., Dossett M. L., Yee C., Greenberg P. D., Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction Cancer Cell 2003 3 5 431 437 (Pubitemid 38340289)
106. Molmed S. P. A., Traversari C., Bordignon C., Antigen transduced T cells used as a delivery system for antigens. WO/2004/035768, 2004
107. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., Bordignon C., HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia Science 1997 276 5319 1719 1724 (Pubitemid 27421983)
108. Clackson T., Yang W., Rozamus L. W., Hatada M., Amara J. F., Rollins C. T., Stevenson L. F., Magari S. R., Wood S. A., Courage N. L., Lu X., Cerasoli F., Gilman M., Holt D. A., Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity Proceedings of the National Academy of Sciences of the United States of America 1998 95 18 10437 10442 (Pubitemid 28413085)
109. Straathof K. C., Spencer D. M., Sutton R. E., Rooney C. M., Suicide genes as safety switches in T lymphocytes Cytotherapy 2003 5 3 227 230 (Pubitemid 37086766)
110. Yeda Research and Development Co, LTD, Eshhar Z., Schindler D., Waks T., Gross G., Chimeric receptor genes and cells transformed therewith. WO/1993/019163, 1993
111. Fred Hutchinson Cancer Research Center, Greenberg P. D., Nelson B. H., Chimeric cytokine receptors in lymphocytes. WO/1994/022914, 1994
112. Topp M. S., Riddell S. R., Akatsuka Y., Jensen M. C., Blattman J. N., Greenberg P. D., Restoration of CD28 expression in CD28 - CD8 + memory effector T cells reconstitutes antigen-induced IL-2 production Journal of Experimental Medicine 2003 198 6 947 955 (Pubitemid 37152931)
113. Sierra Sciences Inc., Andrews W. H., Foster C. A., Fraser S., Mohammadpour H., Methods and compositions for modulating telomerase reverse transcriptase (Tert) expression. WO/2002/016658, 2002
114. Yarden Y., Ullrich A., Growth factor receptor tyrosine kinases Annual Review of Biochemistry 1988 57 443 478
115. Lynch T. J. Jr., Kim E. S., Eaby B., Garey J., West D. P., Lacouture M. E., Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 2007 12 5 610 621 (Pubitemid 350012125)
116. Schrag D., Chung K. Y., Flombaum C., Saltz L., Cetuximab therapy and symptomatic hypomagnesemia Journal of the National Cancer Institute 2005 97 16 1221 1224 (Pubitemid 41258228)
117. Itakura Y., Sasano H., Shiga C., Furukawa Y., Shiga K., Mori S., Nagura H., Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification Cancer 1994 74 3 795 804 (Pubitemid 24237457)
118. Janmaat M. L., Gallegos-Ruiz M. I., Rodriguez J. A., Meijer G. A., Vervenne W. L., Richel D. J., Van Groeningen C., Giaccone G., Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients Journal of Clinical Oncology 2006 24 10 1612 1619 (Pubitemid 46638785)
119. Goldstein N. I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J., Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clinical Cancer Research 1995 1 11 1311 1318
120. Vermorken J. B., Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., Knecht R., Amellal N., Schueler A., Baselga J., Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell
121. Pinto C., di Fabio F., Siena S., Cascinu S., Rojas Llimpe F. L., Ceccarelli C., Mutri V., Giannetta L., Giaquinta S., Funaioli C., Berardi R., Longobardi C., Piana E., Martoni A. A., Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Annals of Oncology 2007 18 3 510 517 (Pubitemid 46359631)
122. Lordick F., Luber B., Lorenzen S., Hegewisch-Becker S., Folprecht G., Wll E., Decker T., Endlicher E., Rthling N., Schuster T., Keller G., Fend F., Peschel C., Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) British Journal of Cancer 2010 102 3 500 505
123. Lorenzen S., Schuster T., Porschen R., Al-Batran S. E., Hofheinz R., Thuss-Patience P., Moehler M., Grabowski P., Arnold D., Greten T., Mller L., Rthling N., Peschel C., Langer R., Lordick F., Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie Annals of Oncology 2009 20 10 1667 1673
124. Yeh K., Hsu C., Hsu C., Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer Journal of Clinical Oncology 2009 27 4567
125. Zhang X., Xu J., Shen L., A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer 39 Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO '09) 2009
126. Pinto C., di Fabio F., Barone C., Siena S., Falcone A., Cascinu S., Rojas Llimpe F. L., Stella G., Schinzari G., Artale S., Mutri V., Giaquinta S., Giannetta L., Bardelli A., Martoni A. A., Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) British Journal of Cancer 2009 101 8 1261 1268
127. Woell E., Khr T., Eisterer W., Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the arbeitsgemeinschaft medikamentoese tumortherapie (AGMT) Anticancer Research 2008 28 2901 2905
128. Gold P., Goldman B., Iqbal S., Leichman L. P., Zhang W., Lenz H. J., Blanke C. D., Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II southwest oncology group study (S0415) Journal of Thoracic Oncology 2010 5 9 1472 1476
129. Ku G., Shah M., Tang L., Cetuximab (C225) plus irinotecan/cisplatin (CPT/ CDDP) for CPT/CDDP-refractory esophageal cancer 54 Proceedings of the Graphics Interface American Society of Clinical Oncology (ASCO '08) 2008
130. Tebbutt N., Cummins M. M., Sourjina T., Australasian Gastro-Intestinal Trials Group. Randomized, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracilor with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial British Journal of Cancer 2010 102 475 481
131. Schnnemann K., Bjerregaard J., Jensen H., Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer 73 Proceedings of the Graphics Interface American Society of Clinical Oncology (GI ASCO '09) 2009
132. Vanhoefer U., Tewes M., Rojo F., Dirsch O., Schleucher N., Rosen O., Tillner J., Kovar A., Braun A. H., Trarbach T., Seeber S., Harstrick A., Baselga J., Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor Journal of Clinical Oncology 2004 22 1 175 184 (Pubitemid 41095130)
133. Rao S., Starling N., Cunningham D., Benson M., Wotherspoon A., Lpfert C., Kurek R., Oates J., Baselga J., Hill A., Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer British Journal of Cancer 2008 99 6 868 874
134. van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J. L., Van Laethem J. L., Maurel J., Richardson G., Wolf M., Amado R. G., Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer Journal of Clinical Oncology 2007 25 13 1658 1664 (Pubitemid 46797944)
135. Foon K., Yang X. D., Weiner L. M., Belldegrun A. S., Figlin R. A., Crawford J., Rowinsky E. K., Dutcher J. P., Vogelzang N. J., Gollub J., Thompson J. A., Schwartz G., Bukowski R. M., Roskos L. K., Schwab G. M., Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody International Journal of Radiation Oncology Biology Physics 2004 58 3 984 990 (Pubitemid 38221160)
136. Casalini P., Iorio M. V., Galmozzi E., Ménard S., Role of HER receptors family in development and differentiation Journal of Cellular Physiology 2004 200 3 343 350 (Pubitemid 39006925)
137. Al-Kasspooles M., Moore J. H., Orringer M. B., Beer D. G., Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas International Journal of Cancer 1993 54 2 213 219 (Pubitemid 23154884)
138. Ross J. S., McKenna B. J., The HER-2/neu oncogene in tumors of the gastrointestinal tract Cancer Investigation 2001 19 5 554 568 (Pubitemid 32619394)
139. Brien T. P., Odze R. D., Sheehan C. E., McKenna B. J., Ross J. S., Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma Human Pathology 2000 31 1 35 39 (Pubitemid 30054384)
140. Hudis C. A., Trastuzumabmechanism of action and use in clinical practice New England Journal of Medicine 2007 357 1 39 51 (Pubitemid 47026733)
141. Piccart-Gebhart M. J., Procter M., Leyland-Jones B., Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer New England Journal of Medicine 2005 353 1659 1672 (Pubitemid 41464705)
142. Romond E. H., Perez E. A., Bryant J., Suman V. J., Geyer C. E., Davidson N. E., Tan-Chiu E., Martino S., Paik S., Kaufman P. A., Swain S. M., Pisansky T. M., Fehrenbacher L., Kutteh L. A., Vogel V. G., Visscher D. W., Yothers G., Jenkins R. B., Brown A. M., Dakhil S. R., Mamounas E. P., Lingle W. L., Klein P. M., Ingle J. N., Wolmark N., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer New England Journal of Medicine 2005 353 16 1673 1684 (Pubitemid 41464706)
143. Smith I., Procter M., Gelber R. D., HERA study team. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial Lancet 2007 369 29 36 (Pubitemid 46039831)
144. Cobleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., Wolter J. M., Paton V., Shak S., Lieberman G., Slamon D. J., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease Journal of Clinical Oncology 1999 17 9 2639 2648 (Pubitemid 29415219)
145. Vogel C. L., Cobleigh M. A., Tripathy D., Gutheil J. C., Harris L. N., Fehrenbacher L., Slamon D. J., Murphy M., Novotny W. F., Burchmore M., Shak S., Stewart S. J., Press M., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer Journal of Clinical Oncology 2002 20 3 719 726 (Pubitemid 34111379)
146. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 New England Journal of Medicine 2001 344 11 783 792 (Pubitemid 32222155)
147. Crone S. A., Zhao Y. Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K. L., Chen J., Kahn R., Condorelli G., Ross J., Chien K. R., Lee K. F., ErbB2 is essential in the prevention of dilated cardiomyopathy Nature Medicine 2002 8 5 459 465 (Pubitemid 34546747)
148. Seidman A., Hudis C., Pierri M. K., Shak S., Paton V., Ashby M., Murphy M., Stewart S. J., Keefe D., Cardiac dysfunction in the trastuzumab clinical trials experience Journal of Clinical Oncology 2002 20 5 1215 1221 (Pubitemid 34177427)
149. Safran H., DiPetrillo T., Akerman P., Ng T., Evans D., Steinhoff M., Benton D., Purviance J., Goldstein L., Tantravahi U., Kennedy T., Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma International Journal of Radiation Oncology Biology Physics 2007 67 2 405 409 (Pubitemid 46108313)
150. Bang J. Y., van Cutsem E., Feyereislova A., ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial Lancet 2010 376 687 697
151. Eskens F. A., Verweij J., The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review European Journal of Cancer 2006 42 18 3127 3139 (Pubitemid 44869016)
152. Ferrara N., Davis-Smyth T., The biology of vascular endothelial growth factor Endocrine Reviews 1997 18 1 4 25 (Pubitemid 27076453)
153. Inoue K., Ozeki Y., Suganuma T., Sugiura Y., Tanaka S., Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression Cancer 1997 79 2 206 213 (Pubitemid 27029883)
154. Kitadai Y., Haruma K., Tokutomi T., Tanaka S., Sumii K., Carvalho M., Kuwabara M., Yoshida K., Hirai T., Kajiyama G., Tahara E., Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas Clinical Cancer Research 1998 4 9 2195 2200 (Pubitemid 28415667)
155. Kleespies A., Guba M., Jauch K. W., Bruns C. J., Vascular endothelial growth factor in esophageal cancer Journal of Surgical Oncology 2004 87 2 95 104 (Pubitemid 39079657)
156. Shih C. H., Ozawa S., Ando N., Ueda M., Kitajima M., Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus Clinical Cancer Research 2000 6 3 1161 1168 (Pubitemid 30159380)
157. Imdahl A., Bognar G., Schulte-Mnting J., Schffel U., Farthmann E. H., Ihling C., Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer European Journal of Cardio-thoracic Surgery 2002 21 4 657 663 (Pubitemid 34257953)
158. Shimada H., Hoshino T., Okazumi S., Matsubara H., Funami Y., Nabeya Y., Hayashi H., Takeda A., Shiratori T., Uno T., Ito H., Ochiai T., Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma British Journal of Cancer 2002 86 4 552 557 (Pubitemid 34185091)
159. Maeda K., Chung Y. S., Ogawa Y., Takatsuka S., Kang S. M., Ogawa M., Sawada T., Sowa M., Prognostic value of vascular endothelial growth factor expression in gastric carcinoma Cancer 1996 77 5 858 863 (Pubitemid 26061277)
160. Yoshikawa T., Tsuburaya A., Kobayashi O., Sairenji M., Motohashi H., Yanoma S., Noguchi Y., Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma Cancer Letters 2000 153 1-2 7 12 (Pubitemid 30209837)
161. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Kabbinavar bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer New England Journal of Medicine 2004 350 23 2335 2342 (Pubitemid 38702844)
162. Sandler A., Gray R., Perry M. C., Brahmer J., Schiller J. H., Dowlati A., Lilenbaum R., Johnson D. H., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer New England Journal of Medicine 2006 355 24 2542 2550 (Pubitemid 44917502)
163. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E. A., Shenkier T., Cella D., Davidson N. E., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New England Journal of Medicine 2007 357 26 2666 2676
164. Jain R. K., Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nature Medicine 2001 7 9 987 989 (Pubitemid 32937367)
165. Willett C. G., Boucher Y., di Tomaso E., Duda D. G., Munn L. L., Tong R. T., Chung D. C., Sahani D. V., Kalva S. P., Kozin S. V., Mino M., Cohen K. S., Scadden D. T., Hartford A. C., Fischman A. J., Clark J. W., Ryan D. P., Zhu A. X., Blaszkowsky L. S., Chen H. X., Shellito P. C., Lauwers G. Y., Jain R. K., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nature Medicine 2004 10 2 145 147 (Pubitemid 38524883)
166. Shah M. A., Ilson D., Kelsen D. P., Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy Journal of Clinical Oncology 2005 23 11 2574 2576 (Pubitemid 47053842)
167. Shah M. A., Jhawer M., Ilson D. H., Lefkowitz R. A., Robinson E., Capanu M., Kelsen D. P., Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma Journal of Clinical Oncology 2011 29 7 868 874
168. Enzinger P., Ryan D., Clark J. W., Muzikansky A., Earle C. C., Kulke M. H., Meyerhardt J. A., Blaszkowsky L. S., Zhu A. X., Fidias P., Vincitore M. M., Mayer R. J., Fuchs C. S., Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer Annals of Oncology 2009 20 3 475 480
169. El-Rayes B., Zalupski M., Bekai-Saab T., Heilbrun L. K., Hammad N., Patel B., Urba S., Shields A. F., Vaishampayan U., Dawson S., Almhanna K., Smith D., Philip P. A., A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers Annals of Oncology 2010 21 10 1999 2004
170. Enzinger P., Fidias P., Meyerhardt J., Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer 68 Proceedings of the Graphics Interface American Society of Clinical Oncology (ASCO '06) 2006
171. Einzig A. I., Neuberg D., Remick S. C., Karp D. D., O'Dwyer P. J., Stewart J. A., Benson A. B., Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293 Medical Oncology 1996 13 2 87 93 (Pubitemid 27019943)
172. Heath E. I., Urba S., Marshall J., Piantadosi S., Forastiere A. A., Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus Investigational New Drugs 2002 20 1 95 99 (Pubitemid 34251655)